B-
BiotechTV - News
STIFEL 2026: Compugen has a trial in ovarian cancer for its PVRIG scheduled to read out in the early part of 2027 - later that year brings the start of Astra's big readouts with the TIGIT bispecific
0:00-10:56
CEO Eran Ophir defines what would be a success in the ovarian trial and possible next steps if successful. Plus, TIGIT, Gilead's work on IL18, and looking for new T-cell engager targets.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-Compugen-has-a-trial-in-ovarian-cancer-for-its-PVRIG-scheduled-to-read-out-in-the-early-part-of-2027---later-that-year-brings-the-start-of-Astras-big-readouts-with-the-TIGIT-bispecific-e3s6cvi
Published
November 11, 2026
Duration
11 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#pvrigscheduled #astrasbigreadouts #tigitbispecific #lifesciences
